Last reviewed · How we verify
Calcineurin inhibitors maintenance
Calcineurin inhibitors maintenance is a Calcineurin inhibitor Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas), Prevention of graft rejection and graft-versus-host disease. Also known as: calcineurin-inhibitors based immunosuppression.
Calcineurin inhibitors suppress T-cell activation by blocking calcineurin phosphatase, preventing IL-2 production and T-cell proliferation.
Calcineurin inhibitors suppress T-cell activation by blocking calcineurin phosphatase, preventing IL-2 production and T-cell proliferation. Used for Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas), Prevention of graft rejection and graft-versus-host disease.
At a glance
| Generic name | Calcineurin inhibitors maintenance |
|---|---|
| Also known as | calcineurin-inhibitors based immunosuppression |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Calcineurin inhibitors (such as tacrolimus and cyclosporine) bind to immunophilins and inhibit calcineurin, a serine/threonine phosphatase essential for T-cell receptor signaling. By blocking calcineurin, they prevent dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing the transcription of IL-2 and other pro-inflammatory cytokines. This mechanism makes them effective for maintenance immunosuppression in transplant recipients.
Approved indications
- Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas)
- Prevention of graft rejection and graft-versus-host disease
Common side effects
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Neurotoxicity (tremor, headache)
- Infections
- Gingival hyperplasia
- Hyperlipidemia
Key clinical trials
- Evaluation of the Impact of Reduced Immunosuppression
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD (PHASE2)
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (PHASE3)
- Dupilumab Therapy in Nephrotic Syndrome in Children (PHASE2)
- Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure (PHASE4)
- Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcineurin inhibitors maintenance CI brief — competitive landscape report
- Calcineurin inhibitors maintenance updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Calcineurin inhibitors maintenance
What is Calcineurin inhibitors maintenance?
How does Calcineurin inhibitors maintenance work?
What is Calcineurin inhibitors maintenance used for?
Who makes Calcineurin inhibitors maintenance?
Is Calcineurin inhibitors maintenance also known as anything else?
What drug class is Calcineurin inhibitors maintenance in?
What development phase is Calcineurin inhibitors maintenance in?
What are the side effects of Calcineurin inhibitors maintenance?
What does Calcineurin inhibitors maintenance target?
Related
- Drug class: All Calcineurin inhibitor drugs
- Target: All drugs targeting Calcineurin (protein phosphatase 2B)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver, pancreas)
- Indication: Drugs for Prevention of graft rejection and graft-versus-host disease
- Also known as: calcineurin-inhibitors based immunosuppression
- Compare: Calcineurin inhibitors maintenance vs similar drugs
- Pricing: Calcineurin inhibitors maintenance cost, discount & access